Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Clinical trial NCT05528952 · RECRUITING
Trial details
- NCT number
- NCT05528952
- Sponsor
- Centre Hospitalier Universitaire de Besancon
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-27
- Primary completion
- 2028-03-27
- Enrollment
- 105
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.